Case Studies

Proof of work

Eleven engagements across Family Offices, Scale-ups and Corporate innovation — challenge, deliverables and measurable outcome for each.

Active / Ongoing In Negotiation In Progress Delivered
01
Capital

Family Offices

3Engagements
1Signed client
$6M+Raised via studio
5+Verticals covered
Family Office · Fund of Funds2026 · Active

Texera Systems

Cyprus-based family office with a Fund of Funds mandate — deploying into Series B+ / growth-stage funds globally, across EU, LATAM, APAC and MENA.

Venture Partner

Challenge

Build a diversified Series B+ Fund of Funds deal pipeline — qualify top-quartile fund managers globally, run introductions, and bridge the family office into the European VC ecosystem for first-time LP positioning.

What I did

  • Investment target scouting across Series B+ growth-stage funds globally, across EU, LATAM, APAC and MENA
  • Deal flow management — 10 named fund candidates screened, scored and prioritised (P0 / P1 / P2)
  • Strategic introductions delivered as signed intros to top-quartile GPs
  • European VC ecosystem bridging — mapped LATAM, APAC and MENA expansion targets for Fund of Funds deployment
10Fund candidates screened
2Signed intros delivered
3Target regions · LATAM · APAC · MENA
Family Office · VC2026 · Active

AmA Invest

8-industry family office (The Hague · Hamburg) with investment arm Pink Elephant VC (Lisbon) deploying Seed–Series A into Mental Health, Psychedelics, Cannabis and Longevity. Portfolio flagships: WeedeN (Thailand's #1 retail cannabis network — 17 stores scaling to 35), States of Mind (Europe's first progressive mental health hub), Claro (AI antidepressants companion), HIVE BIO (neuroscience).

Venture Partner

Challenge

Source a curated pipeline of Mental Health, Brain Health and Psychedelics startups across EU and globally, plus recruit a neuroscience and Big Pharma advisory board for portfolio companies entering clinical-trial stage.

What I did

  • Startup scouting — Mental Health, Brain Health, Psychedelics, Cannabis and Longevity across EU and globally
  • Advisory board formation — 23-contact neuroscience and Big Pharma shortlist for Sonas Pharma (Phase 2 cannabinoid biotech)
  • Venture building — Treatment-Resistant Depression telemedicine play designed from zero
  • Co-investor matching — Paolo Pio (Exceptional Ventures) warm introduction delivered
  • Market intelligence — continuous signal on European cannabis and mental-health ecosystems
23Advisors mapped · Sonas Pharma
8Portfolio companies covered
5+Verticals · EU · APAC · US
Family Office · Holding2021 — 2023

Askona Life Group

$1B+ sleep and wellness holding — part of Hilding Anders International (Swedish-founded global bedding group · ~€1B+ revenue · 8,000+ employees · operations in 40+ countries). Venture studio mandate: build new technology ventures, strategic joint ventures and innovation ecosystem partnerships from zero.

R&D and Venture Studio Director · CEO, Askona Ventures LLC

Challenge

Stand up an internal venture studio inside a $1B+ sleep and wellness conglomerate — launch new products, strategic joint ventures and innovation partnerships across Medical, Smart Home, Mobile/SaaS and Industrial Design verticals.

What I did

  • Venture building — 7 tech startups launched across Russia, UK, Portugal and USA · 50+ innovation projects designed
  • Innovation ecosystem partnerships — Yandex, SberDevices, Sber500, Skolkovo, EMERGE and Web Summit
  • Joint ventures — corporate R&D collaborations across Medical, Smart Home, Mobile/SaaS and Industrial Design
  • Team build-out — 30-person R&D and venture studio team assembled from zero in 12 months
  • Flagship products launched — Somly (sleep tracking) · HESTGARD (luxury smart furniture) · Smart Sofa · Sleep Telemedicine · Sleep Genetics & Microbiota
$6MRaised · $5M Askona + $1M Sleep.8
7Tech startups launched · 50+ projects
30Team members · 4 verticals
02
Growth

Scale-ups

3Engagements
Target valuation uplift
$12M+Combined ARR
5Enterprise pilots
AI · Skincare · B2B2022 — Present

Lóvi.care

AI-native consumer health platform — pivoting from AI Cosmetologist consumer app into B2B AI sales agent for global beauty and supplements brands. Product stack: Face Scanner · Cosmetic Scanner · Fit Score · WhatsApp agent. 900K+ products in the cosmetic database.

Co-founder · B2B Sales & Product Strategy

Challenge

Validate the B2B AI sales agent hypothesis — can Lóvi's AI cosmetologist stack power personalised product recommendations and AOV uplift for enterprise beauty and supplements brands at Mary Kay scale?

What I did

  • B2B AI sales agent hypothesis validated — unit economics and AOV uplift confirmed
  • 5 enterprise pilots launched — global beauty and supplements brands including Mary Kay
  • B2B product development — custom AI agent configurations per brand's assortment and workflow
  • Dev team leadership — AI/ML engineers, mobile and backend · shipped Face Scanner, Cosmetic Scanner, Fit Score, WhatsApp agent
  • Endorsements secured — OpenCV.ai CEO · Google Staff Research Engineer
5Enterprise pilots · Mary Kay tier
+45–67%AOV uplift for B2B partners
900KProducts in cosmetic database
GLP-1 · Diabetes2026 · ActiveIn Progress

Sugar.no

€2.4M ARR metabolic health platform — diabetes and GLP-1/Ozempic management app. Founder Anastasiia Dedova. Preparing for strategic exit into Big Pharma or strategic M&A (target: 2× valuation uplift from PE to strategic).

Fractional BD · Exit & M&A Advisory

Challenge

Double valuation from a financial/PE exit to a strategic pharma acquirer — map the buyer landscape, adapt the product roadmap to strategic buyer playbooks, and place Sugar.no into accelerator and CVC programmes that warm up the acquirer pipeline.

What I do

  • Exit strategy in execution — buyer landscape mapped across Novo Nordisk, Bayer, Biogen, Sanofi, AstraZeneca
  • Roadmap adaptation — product pivots aligned with strategic buyer playbooks (Ozempic / Wegovy ecosystem)
  • Accelerator & CVC placements — curated fits into metabolic-health and pharma programmes for pilots and warm acquirer access
  • Pharma introductions — warm Sanofi connection delivered
  • Benchmark exits mapped — mySugr → Roche ($75–100M) · Veri → Oura
4Exit directions · pharma · M&A · acqui-hire · licensing
22Warm buyer contacts mapped
€2.4MARR · path to strategic exit
Mental Health · Scale-up2026 · ActiveIn Progress

The Coach

$10M ARR mental-health scale-up · 120K MAU · founder Victor Belogub (VAM Apps). Preparing for strategic exit from a PE/financial exit ($30–40M) to a pharma/FMCG strategic acquirer ($60–100M) via enterprise partnerships and co-branding plays.

Fractional CBDO · Exit Priming

Challenge

Own the BD and exit workstream end-to-end for a 12-month engagement — double valuation via pharma, FMCG and men's-health strategic partnerships, parallel-tracking B2B enterprise deals and co-branding plays with strategic acquirers.

What I do

  • Exit strategy in execution — buyer landscape Novo Nordisk · Bayer · Biogen · Sanofi · AstraZeneca · Reckitt/Durex · Hims & Hers · Ro
  • B2B enterprise partnerships — pipeline into pharma, FMCG, insurers, retailers and digital-health buyers
  • Co-branding partnerships — curated brand-adjacent deals in men's health and metabolic wellness
  • Fractional CBO design — Phase 0 (COO sourcing) + Phase 1 (5–8 qualified intros per month)
  • Success-fee structure — 2% of transaction · 18-month tail
Target valuation uplift · PE → strategic
8Strategic buyers mapped & warm
12moEngagement · Phase 0 + Phase 1
03
Innovation

Corporate

5Engagements
3In negotiation
5Pilots signed (MSD)
4,500+Summit participants
Big Pharma · Paris2026In Negotiation

Sanofi

€43B+ revenue global pharmaceutical leader (Paris) · 91,000+ employees across 100 countries. Innovation mandate: source and evaluate lifestyle and data-driven metabolic health startups for strategic M&A into the HealthTech spinoff standing up in Paris.

Startup Scouting · M&A Advisory · Metabolic Health

Challenge

Build a curated M&A pipeline for Sanofi's new-ventures team — lifestyle and data-driven metabolic health startups vetted, qualified and pre-staged for acquisition conversations with the Paris HealthTech spinoff.

What I do

  • Metabolic Health M&A scouting — lifestyle and data-driven startups across EU, US and APAC
  • Curated target pipeline delivered — iCook, Sugar.no, Valeo, Clear Bio, The Coach, OVID/MIND Foundation
  • 6 qualified founder introductions delivered to the Digital Health Advisor
  • Cross-ecosystem networking — bridging my founder and investor network into Sanofi's new-ventures team
6Qualified intros delivered
3moScouting cycle
M&AAdvisory · Ongoing mandate
AI Infrastructure · Amsterdam2026In Negotiation

Nebius

Global AI-centric cloud platform — Amsterdam-listed Nebius Group, ex-Yandex N.V. spin-off. AI/ML infrastructure purpose-built for life sciences and healthcare: drug discovery, genomics, HealthTech imaging and MedTech diagnostics. Products: AI Cloud (AlphaFold2, ESM, ProteinMPNN, BioNeMo) · Token Factory (OpenBioLLM inference) · TractoAI (HPC, multi-omics data processing).

Proposed · Innovation Scouting & Strategic Partnership

Opportunity

Build a curated AI-first HealthTech and BioTech pipeline for Nebius's Life Sciences go-to-market — warm founder introductions, joint events, and use-case-aligned startup scouting across the four core verticals (drug discovery · genomics · HealthTech imaging · MedTech diagnostics).

Proposed scope

  • Curated HealthTech and BioTech startup scouting matched to BioNeMo, OpenBioLLM and AI Cloud use-cases
  • Joint events and founder dinners in London, Amsterdam and Boston
  • Warm introductions into pharma and biotech CVCs for go-to-market acceleration
  • Cross-ecosystem bridging — Family Offices and HealthTech VCs into Nebius AI infrastructure conversations
4Target verticals · Drug · Genomics · HealthTech · MedTech
TargetInnovation scouting & joint events
LiveConversations in progress
Healthcare Data · Boston2026In Negotiation

InterSystems

$1.1B+ revenue healthcare data platform leader — Boston · privately held · 2,400+ employees · 1B+ health records managed globally. Products: IRIS for Health (interoperability-first data platform) · HealthShare (Unified Care Record · HL7 FHIR · V2 · IHE) · TrakCare (hospital information system). Customers include Epic, LabCorp, Sonic and BioReference.

Proposed · Innovation Scouting & Strategic Partnership

Opportunity

Build a curated HealthTech startup scouting pipeline for InterSystems's interoperability, FHIR and healthcare-data verticals — strategic partners and joint go-to-market plays for IRIS for Health and HealthShare across EU, MENA and APAC.

Proposed scope

  • HealthTech and interoperability startup scouting aligned to IRIS, HealthShare and FHIR use-cases
  • Joint events and founder roundtables in London, Boston and Dubai
  • Warm introductions into digital-health scale-ups looking for data-platform partnerships
  • Cross-ecosystem bridging — Family Offices and HealthTech VCs into InterSystems data infrastructure conversations
1B+Health records on InterSystems platform
TargetHealthTech & interoperability scouting
LiveConversations in progress
Big Pharma · American2014 — 2018

Merck (MSD Innovation Factory · MSD Innovation Summit)

$60B+ revenue American pharmaceutical giant (Merck & Co · operating as MSD outside US/Canada) · 68,000+ employees · 140+ country footprint. Mandate: run corporate hackathons and pilots, and produce the flagship MSD Innovation Summit to unite R&D, Market Access, Medical and IT functions globally.

Innovation Lead · IT Business Partner · CIS & EMEA

Challenge

Stand up MSD Innovation Factory as a corporate startup programme — surface real operational challenges (Medical Rep field productivity, drug logistics, HCP education in MENA) and run them through hackathons and pilots. In parallel, produce MSD Innovation Summit as the company's global innovation forum.

What I did

  • MSD Innovation Factory — 2 startup hackathons organised to surface operational innovation challenges (Medical Rep optimisation · drug logistics · HCP education in MENA)
  • 5 startup pilots signed with MSD — from 130 applicants → 3 winners adopted into the organisation
  • MSD Innovation Summit — 3 global summits produced, 90+ countries represented, 4,500+ participants
  • Data & BI stream lead — agenda design, speaker curation, advisory board formation
  • Cross-functional integration — New Drug Development, Market Access, Medical and IT functions united across the summit programme
5Startup pilots signed
3Global summits · 90+ countries
4,500+Summit participants
Pharma · Digital Venture2018 — 2021

Valenta Pharmaceuticals

$500M+ revenue pharmaceutical group. Mandate: stand up the Digital Health and at-home diagnostics Business Unit from zero — source, design and launch new consumer-health ventures across femtech, selfcare and at-home diagnostics.

Head of New Venture Department · COO

Challenge

Stand up Valenta's Digital Health and at-home diagnostics Business Unit from zero — build the innovation funnel, source 500+ global startup and product ideas, design a productised portfolio, and launch two new consumer-facing brands (femtech + selfcare).

What I did

  • Global scouting — 500+ health-tech product and venture ideas sourced across femtech, selfcare and at-home diagnostics
  • Portfolio build-out — 35 products designed across Mother & Baby Care, Urban MedTech and Telemedicine
  • MaMate brand launched — femtech portfolio (smart ovulation test · interactive nebulizer · mobile fetal monitor · male fertility test)
  • M&A and partnerships — 50 business cases built · 8 medical-device agreements signed
  • Strategic partnerships — G4A (Bayer), Biomed/SPLAT, MedTech accelerators
  • Commercial deals — $10M white-label contracts across KR, CN, NL · 11 deals up to $1.5M each
500+Ideas scouted · 35 products designed
2New portfolios launched · femtech + selfcare
$10MWhite-label contracts · KR · CN · NL
The Network

The rolodex you plug into

Not built for your engagement — already running. The ecosystem, the operators and the volume you tap into on day one.

14 Years operator experience · Merck · J&J · Unilever · Valenta · Askona Life
£100M+ Active client pipeline · Convergence EUR 100M · The Coach exit · Sugar.no · AmA
6 Countries lived & operated · NL · UK · TR · PT · RU · FR
5 Therapeutic verticals · Consumer Health · HealthTech · Brain & Metabolic · Women's Health · Longevity
Venture Capital
Convergence Partners Exceptional Ventures Kadmus Ventures Multipliers VC Pink Elephant VC Mill Capital
Big Pharma & Corporates
Sanofi Merck & Co (MSD) Johnson & Johnson Unilever Valenta Pharmaceuticals Askona · Hilding Anders Nebius InterSystems
CVCs & Accelerators
Bayer G4A Skolkovo SberDevices · Sber500 Web Summit EMERGE
Advisors & KOLs
Neuroscience PhDs Psychedelics & cannabinoid clinical Metabolic Health Digital therapeutics clinical Regulatory · FDA · CE · MHRA

Advisors recruited per engagement. Recent example: 23-contact neuroscience and Big Pharma shortlist for Sonas Pharma (Phase 2 cannabinoid biotech · AmA Invest portfolio).

Family Offices & Principals

Family Office principals across EU and the Gulf — introductions made under mutual NDA only.

Which case looks most like yours?

Book a 30-min discovery call — I'll tell you in plain English whether I can actually help.

Book a discovery call →